Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
Subscribe To Our Newsletter & Stay Updated
